Evidence map›Paper›PMID 30148147›Full record

ArticleWorld journal of clinical cases2018

Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer.

Cheng Lou, Tong Bai, Le-Wei Bi, Ying-Tang Gao, Zhi Du

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical cases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Cheng LouDepartment of Hepatobiliary Surgery, Third Central Hospital of Tianjin, Tianjin 300170, China.
Tong BaiDepartment of Hepatobiliary Surgery, Third Central Hospital of Tianjin, Tianjin 300170, China.
Le-Wei Bithe Graduate School of Tianjin Medical University, Tianjin 300070, China.
Ying-Tang GaoTianjin Institute of Hepatobiliary Disease, Tianjin 300170, China.
Zhi DuDepartment of Hepatobiliary Surgery, Third Central Hospital of Tianjin, Tianjin 300170, China.
Tianjin Medical University · CNTianjin Fire Research Institute · CNTianjin Third Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess the impact of hepatitis B surface (HBsAg) seroclearance on survival outcomes in hepatitis B-related primary liver cancer.

methodsInformation from patients with hepatitis B-related liver cancer admitted in our hospital from 2008-2017 was retrieved. Cases diagnosed with HBsAg (-) and HBcAb (+) liver cancer were included in the HBsAg seroclearance (SC) group. HBsAg (+) liver cancer patients strictly matched for liver cancer stage (AJCC staging system, 8

resultsThe SC and NSC groups comprised of 72 and 216 patients, respectively. Patient age (

conclusionSeroclearance in patients with hepatitis B-related primary liver cancer has protective effects with respect to tumorigenesis, cirrhosis, and portal hypertension but confers worse prognosis, which may be due to the frequent occurrence of highly malignant ICC and CHC.

Indexed as

Chronic hepatitis BHepatitis B surfaceHepatitis B surface seroclearancePrimary liver cancerPrognosis

Identifiers

PMID30148147
PMCPMC6107526
OpenAlexW2885361288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.